Moteur de recherche d’entreprises européennes
Financement de l’UE (3 687 312 €) : Une plateforme intégrée pour le développement de techniques de diagnostic du cancer du cerveau Hor 28/08/2017 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Une plateforme intégrée pour le développement de techniques de diagnostic du cancer du cerveau
The mission of AiPBAND is to train a new generation of entrepreneurial and innovative early-stage researchers (ESRs) in the early diagnosis of brain tumours using molecular biomarkers in the blood, meeting the medical and societal challenges of this emerging field. AiPBAND will focus on gliomas, a range of devastating and progressive brain tumours affecting around 25,000 people each year in Europe and responsible for the majority of deaths from primary brain tumours. Fourteen fellows will be trained by experts in 9 academic and 3 non-academic beneficiaries, belonging to 5 EU member states and 6 partner organizations (4 private sectors and 2 international academic), with fields ranging from neuroscience, engineering (including big data science), healthcare to economics. State-of-the-art technologies will be applied in parallel to (i) identify novel blood biomarkers from patients with gliomas, (ii) design three types of multiplex biosensor (plasmonic-based, graphene-based, and digital ELISA assay-based), (iii) develop a big data-empowered intelligent data management infrastructure, and (iv) develop cloud-based diagnostic systems. Proof-of-concept will be evaluated through clinical trials to assess accuracy, sensitivity and specificity. The elaborately designed individual research projects under the Vitae Researcher Development Framework – carefully arranged into local training courses, network wide events, secondments, personalized career development plans, with strong involvement of the private sector – will ensure exploitation of AiPBAND's achievements, and will maximize the ESRs’ abilities in creative & innovative thinking, triple-i knowledge transformation, and encourage a business-orientated mind-set and entrepreneurship.
| B. Braun Melsungen AG | ? |
| Imperial College of Science Technology and Medicine | 273 288 € |
| Istituti Fisioterapici Ospitalieri | 258 061 € |
| Karolinska Institutet | 263 659 € |
| Katholieke Universiteit Leuven | 250 560 € |
| Medical Trials Analysis Italy Srl | 306 089 € |
| Prinses Maxima Centrum Voor Kinderoncologie B.V. | 198 624 € |
| Scriba Nanotecnologie Srl | 210 033 € |
| Stichting Radboud Universiteit | 56 750 € |
| Stockholms Universitet | 263 659 € |
| Teesside University | 220 149 € |
| THE Hyve B.V. | 255 374 € |
| Universita Degli Studi Di Catania | 258 061 € |
| University College London | 273 288 € |
| University of Plymouth | 599 715 € |
https://cordis.europa.eu/project/id/764281
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : B. Braun Melsungen AG, Melsungen, Allemagne.
